<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2000
-----------------
MAGAININ PHARMACEUTICALS INC.
-----------------------------------
(Exact name of registrant specified in charter)
Delaware 0-19651 13-3445668
-------- -------- ----------
(State or other (Commission File (I.R.S. Employer
jurisdiction of Number) Identification No.)
incorporation)
5110 Campus Drive
Plymouth Meeting, PA 19462
-----------------------------------------------------
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (610) 941-4020
----------------------
================================================================================
<PAGE>
Item 5. Other Events.
The registrant hereby incorporates by reference the press release dated
November 16, 2000 attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements of Business Acquired: Not applicable.
(b) Pro Forma Financial Information: Not applicable.
(c) Exhibits:
Exhibit No. Description
----------- -----------
99.1 Press Release dated November 16, 2000 - Magainin's Anti-
Angiogenic Compound, Squalamine, Shows Activity in Lung Cancer
Trial.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MAGAININ PHARMACEUTICALS INC.
Dated: November 16, 2000 By: /s/ Michael R. Dougherty
-----------------------------------------------
Michael R. Dougherty
President and Chief Executive Officer
3
<PAGE>
EXHIBIT INDEX
-------------
Exhibit No. Description
----------- -----------
99.1 Press Release dated November 16, 2000 - Magainin's Anti-
Angiogenic Compound, Squalamine, Shows Activity in Lung Cancer
Trial.
4
